Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations.

The lactoferrin (Lf) conjugated poly (ethyleneglycol)-poly (lactide) nanoparticle (Lf-NP) was constructed in this paper as a novel biodegradable brain drug delivery system with evaluation of its in vitro and in vivo delivery properties. Lf was thiolated and conjugated to the distal maleimide functions surrounding on the pegylated nanoparticles to form the Lf-NP. The existence of Lf on the surface of Lf-NP was verified by TEM observation and XPS analysis. The Lf ELISA results confirmed the biorecognitive activity of Lf after the coupling procedure and suggested the average number of Lf conjugated on each nanoparticle was around 55. To evaluate the brain delivery properties of the Lf-NP, a fluorescent probe, coumarin-6 was incorporated into it. The uptake of Lf-NP by bEnd.3 cells was shown significantly higher than that of unconjugated nanoparticle (NP). Following an intravenous administration, a near 3 folds of coumarin-6 were found in the mice brain carried by Lf-NP compared to that carried by NP. Cell viability experiment results confirmed good safety of the biodegradable Lf-NP. The significant in vitro and in vivo results suggest that Lf-NP is a promising brain drug delivery system with low toxicity.

[1]  Y. Suzuki,et al.  Mammalian lactoferrin receptors: structure and function. , 2005, Cellular and molecular life sciences : CMLS.

[2]  J. Huwyler,et al.  Brain drug delivery of small molecules using immunoliposomes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Y Agid,et al.  Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Xingrong Liu,et al.  Strategies to optimize brain penetration in drug discovery. , 2005, Current opinion in drug discovery & development.

[5]  L. Fenart,et al.  Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier* , 1999, The Journal of Biological Chemistry.

[6]  Jean-Christophe Olivier,et al.  Drug transport to brain with targeted nanoparticles , 2011, NeuroRX.

[7]  H. Lee,et al.  Synthesis of Pegylated Immunonanoparticles , 2002, Pharmaceutical Research.

[8]  Amarnath Sharma,et al.  Liposomes in drug delivery: Progress and limitations , 1997 .

[9]  M. Jameson,et al.  Early experience with novel immunomodulators for cancer treatment , 2007, Expert opinion on investigational drugs.

[10]  Rachel C Brown,et al.  Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells , 2007, Brain Research.

[11]  A. Boer,et al.  Strategies to Improve Drug Delivery Across the Blood-Brain Barrier , 2007, Clinical pharmacokinetics.

[12]  G. Storm,et al.  Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  D. Bazile,et al.  Comparison of the safety profiles of PLA50 and Me.PEG-PLA50 nanoparticles after single dose intravenous administration to rat , 1999 .

[14]  W. Pardridge.  Drug Targeting to the Brain , 2007, Pharmaceutical Research.

[15]  Yan Zhang,et al.  Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[16]  D. Walker,et al.  Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. , 1993, The American journal of pathology.

[17]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[18]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[19]  P. V. Berkel,et al.  Structure and biological actions of lactoferrin , 1996, Journal of Mammary Gland Biology and Neoplasia.

[20]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[21]  T. Suhara,et al.  Pharmacokinetics and brain uptake of lactoferrin in rats. , 2006, Life sciences.

[22]  M. Ricci,et al.  Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? , 2006, Current medicinal chemistry.

[23]  Rongqin Huang,et al.  Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. , 2007, Journal of biomedical science.

[24]  W. Pardridge,et al.  Antisense gene therapy of brain cancer with an artificial virus gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  S. Feng,et al.  Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. , 2004, Biomaterials.

[26]  P. Couvreur,et al.  Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? , 2005, International journal of pharmaceutics.

[27]  D. Begley.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[28]  Xin-guo Jiang,et al.  Preparation, characterization and application of pyrene-loaded methoxy poly(ethylene glycol)–poly(lactic acid) copolymer nanoparticles , 2004 .

[29]  W. Fogel,et al.  Assessment of plasma lactoferrin in Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[30]  F. Calon,et al.  Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. , 2003, Human gene therapy.

[31]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[32]  C Vigneron,et al.  Protein C-loaded monomethoxypoly (ethylene oxide)-poly(lactic acid) nanoparticles. , 2001, International journal of pharmaceutics.

[33]  Robert Langer,et al.  Tissue Engineering: A New Field and Its Challenges , 1997, Pharmaceutical Research.

[34]  V. Labhasetwar,et al.  Characterization of nanoparticle uptake by endothelial cells. , 2002, International journal of pharmaceutics.

[35]  Afsaneh Lavasanifar,et al.  Amphiphilic block copolymers for drug delivery. , 2003, Journal of pharmaceutical sciences.

[36]  Jayanth Panyam,et al.  Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. , 2003, International journal of pharmaceutics.

[37]  Y. Ikada,et al.  Tissue Reaction of Bioabsorbable Ultra High Strength Poly (L‐Lactide) Rod: A Long‐Term Study in Rabbits , 1995, Clinical orthopaedics and related research.

[38]  W. Pardridge,et al.  Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. , 2004, Human gene therapy.

[39]  E. Morgan,et al.  Restricted transport of anti‐transferrin receptor antibody (OX26) through the blood–brain barrier in the rat , 2001, Journal of neurochemistry.

[40]  Gordon L. Amidon,et al.  The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent , 1997, Pharmaceutical Research.

[41]  K. Yamauchi,et al.  Bovine lactoferrin and lactoferricin derived from milk: production and applications. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.